News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BrainStorm Cell Therapeutics Inc. Receives US Notice Of Allowance For Its Key Stem Cell Technology Patent


2/3/2014 8:41:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its “Mesenchymal Stem Cells for the Treatment of CNS Diseases” (serial number 12/994,761) patent application.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES